Please select the option that best describes you:
Topics:
Medical Oncology
What are your top takeaways in Hematologic Malignancies from ASCO 2024?
Answer from: Medical Oncologist at Academic Institution
The top three would be
IMROZ
DREAMM-8
BENEFIT
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I would say I’m a DREAMMer :)The DREAMM-8 (BPd vs PVd) results were truly impressive.Both DREAMM-7 and DREAMM-8 trials illustrate how well Belantamab Mafodotin pairs with proteasome inhibitors and immunomodulatory agents. In addition, for patients with relapsed refractory myeloma, having been ...
Answer from: at Community Practice
Always an exciting conference for myeloma and this year was no exception.1. IMROZ study: The management of newly diagnosed multiple myeloma (NDMM) has evolved significantly over the past few years. One of the first clinical assessments in planning treatment is determining eligibility for autologous ...
Answer from: Medical Oncologist at Academic Institution
The DREAMM-7 and DREAMM-8: Impressive results in terms of PFS. Will likely lead to the reintroduction of belantamab into clinical practice and offer another potential BCMA-based therapy amenable to administration in the community setting. IMROZ: Will lead to the ability to give “Isatuxima...
Answer from: Medical Oncologist at Academic Institution
For multiple myeloma, my "top 3" presentations were:
BENEFIT/IFM 2020-05 study (Leleu et al., #7501) - Isa-VRd with once-weekly bortezomib beat Isa-Rd in transplant-ineligible patients with regard to MRD negativity (PFS results still pending). This study is getting overshadowed by IMROZ, which is u...